Global pharmaceutical company Lupin Limited has entered into a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for the commercialization of Tiotropium Dry Powder Inhaler (DPI), 18 mcg/capsule, in China. The medication is used for managing chronic obstructive pulmonary disease (COPD).
Under the terms of the agreement, SUP will handle regulatory approvals and commercial distribution in China, while Lupin will act as the marketing authorization holder and continue manufacturing the product. Tiotropium DPI is widely recognized for improving lung function and enhancing the quality of life for patients with respiratory ailments.
"This collaboration marks a significant step in expanding our presence in China’s growing healthcare market and providing timely access to high-quality respiratory therapies,” said Fabrice Egros, President of Corporate Development at Lupin. “Our partnership with SUP reinforces Lupin’s commitment to respiratory health and delivering innovative solutions to patients worldwide."
Wang Li, President of SUP, added, “We are proud to collaborate with Lupin, a global leader in respiratory treatments. This partnership supports our goal of introducing advanced, effective therapies to Chinese patients and advancing respiratory care across the region.”